Key Points
- COO Gianluca Pettiti sold 400 shares on April 27 at an average price of $462.66 for total proceeds of $185,064 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 1.57% to 25,051 shares valued at about $11.59M.
- Thermo Fisher beat Q1 estimates with EPS of $5.44 versus $5.25 and revenue of $11.01B (up 6.2% YoY), and issued FY2026 EPS guidance of 24.640–25.120.
- The company increased its quarterly dividend to $0.47 (annualized $1.88, yield ~0.4%), and analysts collectively rate the stock a "Buy" with an average target price of $623.05.
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) COO Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gianluca Pettiti also recently made the following trade(s):
- On Monday, February 9th, Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock. The shares were sold at an average price of $541.20, for a total value of $216,480.00.
Thermo Fisher Scientific Stock Down 0.9%
Shares of NYSE:TMO opened at $466.04 on Thursday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The stock's fifty day simple moving average is $496.82 and its 200-day simple moving average is $548.19. The company has a market capitalization of $173.19 billion, a P/E ratio of 25.62, a P/E/G ratio of 2.07 and a beta of 0.97.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. During the same period in the prior year, the business earned $5.15 earnings per share. The business's revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 24.83 earnings per share for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a $0.47 dividend. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.
Institutional Investors Weigh In On Thermo Fisher Scientific
Several institutional investors and hedge funds have recently added to or reduced their stakes in TMO. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $28,000. JPL Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at about $28,000. Beacon Financial Strategies CORP acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Finally, Olistico Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. TD Cowen reduced their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research report on Friday, January 30th. Morgan Stanley reiterated an "overweight" rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday. Stifel Nicolaus reduced their target price on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a research report on Friday, April 24th. Citigroup increased their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $623.05.
View Our Latest Report on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
